2022 HIV Market Report
A framework to support new product introduction in national health systems
Resource Library


- Aug 30, 2022
The Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study

- May 31, 2022
2022 CHAI HIV Mid-Year Market Memo

- May 24, 2022
GAP-f pDTG Implementation Considerations for National Programmes

- Apr 13, 2022
Adult DRV/r (400/50mg) FAQs for Communities and PLHIV

- Mar 17, 2022
Adult DRV/r (400/50mg) Clinical Action Memo

- Mar 16, 2022
CHAI DRV/r 2L Product Profile

- Mar 16, 2022
DRV/r (400/50mg) FAQs

- Nov 16, 2021
2021 Regional HIV Market Briefs

- Oct 11, 2021
Pediatric DTG FAQs

- Oct 11, 2021
2021 HIV Market Report

- Oct 11, 2021
CHAI Pediatric DTG Product Profile

- Oct 11, 2021
Pediatric DTG Implementation Memo (English, French)

- Sep 20, 2021
ALSM Diagnostic Pricing Database

- Sep 16, 2021
HIV i-Base Resources

- Aug 16, 2021
Pediatric DTG Introduction: Transition Plan Templates


- Jul 31, 2021
2021 WHO Guidelines


- Jul 21, 2021
2021 CHAI HIV Mid-Year Market Memo

- Jul 19, 2021
Transitioning to the 2021 WHO optimal formulary for antiretroviral drugs for children

- Jul 16, 2021
WHO Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring